Possible Effects of GLP-1 Receptor Agonists on Fertility in Women with Polycystic Ovary Syndrome

Women with polyendocrine metabolic ovarian syndrome (PMOS) experience a combination of reproductive dysfunction, obesity, insulin resistance, and chronic inflammation.

• PMOS is associated with multiple endocrine and metabolic issues, complicating treatment.
• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) could potentially provide a new treatment option for PMOS.
• The use of GLP-1RAs may address the underlying endocrine and reproductive disturbances seen in PMOS.

Simplified